Eagle Pharmaceuticals (Eagle Pharmaceuticals) Debt-to-Equity : 0.28 (As of Jun. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Eagle Pharmaceuticals Debt-to-Equity?

Eagle Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was $9.7 Mil. Eagle Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was $61.9 Mil. Eagle Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Jun. 2023 was $252.0 Mil. Eagle Pharmaceuticals's debt to equity for the quarter that ended in Jun. 2023 was 0.28.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Eagle Pharmaceuticals's Debt-to-Equity or its related term are showing as below:

EGRX' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.13 Med: 0.25 Max: 0.83
Current: 0.28

During the past 11 years, the highest Debt-to-Equity Ratio of Eagle Pharmaceuticals was 0.83. The lowest was 0.13. And the median was 0.25.

EGRX's Debt-to-Equity is ranked better than
50.35% of 856 companies
in the Drug Manufacturers industry
Industry Median: 0.28 vs EGRX: 0.28

Eagle Pharmaceuticals Debt-to-Equity Historical Data

The historical data trend for Eagle Pharmaceuticals's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eagle Pharmaceuticals Debt-to-Equity Chart

Eagle Pharmaceuticals Annual Data

Trend

Sep13

Sep14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Debt-to-Equity

Get a 7-Day Free Trial

0.28

0.23

0.18

0.17

0.27

Eagle Pharmaceuticals Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
Debt-to-Equity	Get a 7-Day Free Trial															0.23	0.28	0.27	0.32	0.28

Competitive Comparison of Eagle Pharmaceuticals's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Eagle Pharmaceuticals's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Eagle Pharmaceuticals's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Eagle Pharmaceuticals's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Eagle Pharmaceuticals's Debt-to-Equity falls into.

Eagle Pharmaceuticals Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Eagle Pharmaceuticals's Debt to Equity Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(7.784	+	56.216)	/	233.56
	=	0.27

Eagle Pharmaceuticals's Debt to Equity Ratio for the quarter that ended in Jun. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(9.719	+	61.896)	/	252.04
	=	0.28

Eagle Pharmaceuticals (NAS:EGRX) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Eagle Pharmaceuticals Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Eagle Pharmaceuticals's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Eagle Pharmaceuticals (Eagle Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Eagle Pharmaceuticals Inc (NAS:EGRX) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

1E6:Germany

Address

50 Tice Boulevard, Suite 315, Woodcliff Lake, NJ, USA, 07677

Website

http://www.eagleus.com

Eagle Pharmaceuticals Inc is a specialty pharmaceutical company. The company develops and commercializes injectable products in the areas of critical care, orphan diseases, and oncology. Its product portfolio consists of four approved products: Argatroban, Ryanodex, Belrapzo, and Bendeka. The company currently has multiple product candidates in advanced stages of development and is under review for approval by the Food and Drug Administration.

Executives

Scott Tarriff	director, officer: President and CEO	28 TUDOR ROSE TERRACE, MAHWAH NJ 07430
Richard A. Edlin	director	C/O EAGLE PHARMACEUTICALS, INC., 50 TICE BOULEVARD, SUITE 315, WOODCLIFF LAKE NJ 07677
Michael Shawn Moran	officer: EVP, Chief Commercial Officer	C/O EAGLE PHARMACEUTICALS, INC., 50 TICE BLVD., SUITE 315, WOODCLIFF NJ 07677
Luciana Borio	director	C/O EAGLE PHARMACEUTICALS, INC., 50 TICE BLVD., SUITE 315, WOODCLIFF LAKE NJ 07677
Brian Joseph Cahill	officer: Chief Financial Officer	C/O EAGLE PHARMACEUTICALS, INC., 50 TICE BOULEVARD, SUITE 315, WOODCLIFF LAKE NJ 07677
Judith Ng-cashin	officer: Chief Medical Officer	C/O EAGLE PHARMACEUTICALS, INC., 50 TICE BOULEVARD, SUITE 315, WOODCLIFF LAKE NJ 07677
Hudson Executive Capital Lp	director	C/O CADWALADER, WICKERSHAM & TAFT, LLP, 200 LIBERTY STREET, NEW YORK NY 10281
Hec Management Gp Llc	director	1185 AVENUE OF THE AMERICAS, 32ND FLOOR, NEW YORK NY 10036
Jennifer K. Simpson	director	C/O DELCATH SYSTEMS, INC., 810 SEVENTH AVENUE, SUITE 3505, NEW YORK NY 10019
Douglas L Braunstein	director	HUDSON EXECUTIVE CAPITAL LP, 570 LEXINGTON AVENUE, 35TH FLOOR, NEW YORK NY 10022
Sander A Flaum	director	630 PARK AVE, NEW YORK NY 10019
Pete A. Meyers	officer: Chief Financial Officer	C/O TETRALOGIC PHARMACEUTICALS CORP, 343 PHOENIXVILLE PIKE, MALVERN PA 19355
David Pernock	director	405 EAGLEVIEW BOULEVARD, EXTON PA 19341
Proquest Investments Iv, L.p.	10 percent owner	2430 VANDERBILT BEACH ROAD, #108 - 190, NAPLES FL 34109
Steven L. Krill	officer: Chief Scientific Officer	C/O EAGLE PHARMCEUTICALS, INC., 50 TICE BLVD. SUITE 315, WOODCLIFF LAKE NJ 07677